Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy Evaluation of a Leuprorelin Formulation (Lorelin Depot Injection®) by Determination of Serum Testosterone in Rats

혈청 테스토스테론 농도 측정에 의한 로렐린 데포 주사제의 약효 비교 시험

  • Lee, Hye-Ju (Department of Pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Hwang, Seong-Mee (Department of Pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Shim, Won-Sik (Department of Pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Jung, Goo-Young (Research Dept, Dongkook Pharm. Co., LTD.) ;
  • Son, Kyung-Chul (Marketing Dept, Dongkook Pharm. Co.,LTD.) ;
  • Kim, Dae-Duk (Department of Pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Chung, Suk-Jae (Department of Pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Shim, Chang-Koo (Department of Pharmaceutics, College of Pharmacy, Seoul National University)
  • Published : 2009.02.20
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to compare the efficacy of Lorelin Depot $Injection^{(R)}$ (Dongkook Pharm. Co., LTD) with Lucrin Depot $Injection^{(R)}$ (Abbott) by measuring serum testosterone level in rats. Leuprorelin (leuprolide acetate), which is an active compound for the two formulations, is an LHRH analogue that is used for the treatment of a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. Lorelin Depot $Injection^{(R)}$ is a micro-encapsulated formulation to suppress testosterone level by releasing leuprorelin continuously for four weeks with a single subcutaneous injection. The comparison study of the efficacy was performed during four weeks, and serum testosterone levels were monitored in the two formulations. The mean serum testosterone levels from the formulations were decreased to that of the castrate range (50 ng/dL or less) after three days after the initial depot injection, and the concentration were remained throughout four weeks' period. There were no significant differences in the $AUC_{0-3day}$ of testosterone and testosterone levels at 3, 7, 14, 21 and 28 days between the two formulations. These results indicate that the two formulations, Lorelin Depot $Injection^{(R)}$ and Lucrin Depot $Injection^{(R)}$, are bioequivalent in terms of the serum testosterone level in rats.

Keywords

References

  1. M. Fujino, T. Fukuda, S. Shinagawa, S. Kobayashi, I. Yamazaki, R. Nakayama, J.H. Seely, W.F. White and R.H Rippel, Synthetic analogs of luteinizing hormone-releasing hormone (LH-RH) substituted in position 6 and 10, Biochem. Biophys. Res. Commun., 60, 406-413 (1974). https://doi.org/10.1016/0006-291X(74)90219-8
  2. H. Toguchi, Y. Ogawa, H. Okada and M. Yamamoto, Oncea- month injectable microcapsules of leuprorelin acetate (Japanese), Yakugaku Zasshi, 111, 397-409 (1991).
  3. T.W. Redding and A.V. Schally, Inhibition of prostate tumor 6 growth in two rat models by chronic administration of DTrp analogue of luteinizing hormone-releasing hormone, Proc. Natl. Acad. Sci. USA, 78, 6509-6512 (1981). https://doi.org/10.1073/pnas.78.10.6509
  4. N. Faure, F. Labrie, A. Lemay, A. Belanger, Y. Gourdeau, B. Laroche and G. Robert, Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men, Fertil. Steril., 37, 416-424 (1982). https://doi.org/10.1016/S0015-0282(16)46107-8
  5. The Leuprolide Study Group, Leuprolide versus diethylstilbestrol for metastatic prostate cancer, N. Engl. J. Med.,311, 1281-1286 (1984). https://doi.org/10.1056/NEJM198411153112004
  6. E.S. Johnson, J.H. Seely, W.F. White and E.R. DeSombre, Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog, Science, 194, 329-330 (1976). https://doi.org/10.1126/science.823643
  7. E.R. DeSombre, E.S. Johnson and W.F. White, Regression of rat mammary tumors effected by a gonadoliberin analog, Cancer Res., 36, 3830-3833 (1976).
  8. S.K. Park, L.C. Sakoda, D. Kang, A.P. Chokkalingam, E. Lee, H.R. Shin, Y.O. Ahn, M.H. Shin, C.W. Lee, D.H. Lee, A. Blair, S.S. Devesa and A.W. Hsing, Rising prostate cancer rates in South Korea, The Prostate, 66, 1285-1291 (2006). https://doi.org/10.1002/pros.20419
  9. Y.W. Chien, Systemic delivery of peptide-based pharmaceuticals, in: J. Swarbrick (Ed.), Drugs and the Pharmaceutical Sciences 50, Novel Drug Delivery Systems, 2nd ed., Marcel Dekker, New York, pp. 631-745 (1992)
  10. H. Okada, I. Yamazaki, Y. Sakura, T. Yashiki, T. Shimamoto and H. Mima, Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats, J. Pharm. Dyn., 6, 512-522 (1983). https://doi.org/10.1248/bpb1978.6.512
  11. H. Okada, Y. Doken, Y. Ogawa and H. Toguchi, Preparation of three month depot injectable microspheres of leuprorelin acetate using biodegradable polymers, Pharm. Res., 11, 1143-1147 (1994). https://doi.org/10.1023/A:1018936815654
  12. R.H. Asch, F.J. Rojas, A. Bartke, A.V. Schally, T.R. Tice, H.G.Klemcke, T.M. Silerkhodr, R.E. Bray and M.P. Hogan, Prolonged suppression of plasma LH levels in male rats after a single injection of an LHRH agonist in poly (dllactide-co-glycolide) microcapsules, J. Androl., 6, 83-88 (1985). https://doi.org/10.1002/j.1939-4640.1985.tb00821.x
  13. K.J. Walker, A.O. Turkes, A. Turkes, R. Zwink, C. Beacock, A. Buck, W.B. Peeling and K. Griffiths, Treatment of patients with advanced cancer of prostate using a slowrelease (depot) formulation of the LHRH agonist ICI 118630 ($Zoladex^{(R)}$), J. Endocrinol., 103, R1-R4 (1984). https://doi.org/10.1677/joe.0.103R001
  14. H. Okada, Y. Ogawa and T. Yashiki, Prolonged release microcapsule and its production. US Patent, 4,652,441, 1987 (Jpn. Patent Appl. 207760/1983, November 4, 1983).
  15. M. Yamamoto, S. Takada and Y. Ogawa, Method for producing microcapsule, Jpn. Patent Appl. 22978, February 7 (1985).
  16. Y. Ogawa, M. Yamamoto, H. Okada, Y. Yashiki and T. Shimamoto, A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid, Chem. Pharm. Bull., 36, 1095-1103 (1988). https://doi.org/10.1248/cpb.36.1095
  17. H. Okada, T. Heya, Y. Ogawa, H. Toguchi and T. Shimamoto, Sustained pharmacological activities in rats following single and repeated administration of once-amonth injectable microspheres of leuprolide acetate, Pharm. Res., 8, 584-587 (1991). https://doi.org/10.1023/A:1015844421319
  18. H. Okada, Y. Inoue, T. Heya, H. Ueno, Y. Ogawa and H. Toguchi, Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate, Pharm. Res., 8, 787-791 (1991). https://doi.org/10.1023/A:1015818504906
  19. T.G. Shrivastav, A. Basu and K.P. Kariya, One step enzyme linked immunosorbent assay for direct estimation of serum testosterone, J. Immunoassay Immunochem., 24, 205-217 (2003). https://doi.org/10.1081/IAS-120020085
  20. A.S. Pathak, J.S. Pacificar, C.E. Shapiro and S.G. Williams, Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study, J. Urol., 177, 2132-2135 (2007). https://doi.org/10.1016/j.juro.2007.01.157
  21. P. Periti, T. Mazzei and E. Mini, Clinical pharmacokinetics of depot leuprorelin, Clin. Pharmacokin., 41, 485-504 (2002). https://doi.org/10.2165/00003088-200241070-00003
  22. H.B. Ravivarapua, K. Burtonb and P.P. DeLuca, Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres, Eur. J. Pharm. Biopharm., 50, 263-270 (2000). https://doi.org/10.1016/S0939-6411(00)00099-0